IIM
RXRX icon

IFC & Insurance Marketing’s Recursion Pharmaceuticals RXRX Stock Holding History

IFC & Insurance Marketing’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,500
Closed -$6K – 551
2025
Q4 		$6K Buy
+1,500
New +$7.43K 0.01% 481

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IFC & Insurance Marketing's RXRX Position: Q1 2026 in Review

IFC & Insurance Marketing sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 1,500 shares — an estimated $6K sold.

IFC & Insurance Marketing first reported a position in RXRX in Q4 2025 and held it in 1 quarter. The position peaked at $6K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • IFC & Insurance Marketing reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • IFC & Insurance Marketing sold 1,500 Recursion Pharmaceuticals shares in Q1 2026, an estimated $6K.
  • IFC & Insurance Marketing first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • IFC & Insurance Marketing's Recursion Pharmaceuticals position peaked at $6K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on IFC & Insurance Marketing's 13F filing for Q1 2026, filed 17 Apr 2026.